Our manuscript describing our drug repurposing screen and the identification of masitinib as a bone-fide inhibitor of the main viral protease (3CLpro) has been published by Science and is available here: https://science.sciencemag.org/lookup/doi/10.1126/science. abg5827
Our manuscript describing the drug repurposing screen and the identification of masitinib as a bone-fide inhibitor of the main viral protease (3CLpro) is now live on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.08.31.274639v1
Updated 9/25/20: This pre-print has generated considerable attention. It is in the 99 percntile of all papers tracked by Altmetric and has been downloaded form bioRxiv over 1,000 times!
From March 2020, my studies have shifted to help the local and global efforts to understand coronavirus biology and identify anti-viral therapies.
Using HCoV-OC43, a beta-coronavirus that causes the common cold, I performed a drug repurposing screen – testing 1,900 clinically approved drugs for their ability to inhibit OC43 replication in vitro.
Of the 108 identified hits we chose the top 26 drugs for further characterization against SARS CoV2. 20/26 drugs showed efficacy in inhibiting SARS CoV2 replication in human lung cancer cells.
I am currently following up on the most promising drugs, investigating their mechanism of action. We plan to pursue clinical trials in the near future.